z-logo
Premium
Gemcitabine‐associated CD8+ CD30+ pseudolymphoma
Author(s) -
Marucci G.,
Sgarbanti E.,
Maestri A.,
Calandri C.,
Collina G.
Publication year - 2001
Publication title -
british journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.304
H-Index - 179
eISSN - 1365-2133
pISSN - 0007-0963
DOI - 10.1046/j.1365-2133.2001.04461.x
Subject(s) - gemcitabine , pseudolymphoma , medicine , lesion , pathology , lymphoma , stage (stratigraphy) , chemotherapy , paleontology , biology
We describe a 69‐year‐old man with a non‐small cell carcinoma of the lung, stage III B, who developed bilateral multiple erythematous lesions in the abdominal–inguinal area following treatment with gemcitabine. Histologically, the lesion was characterized by a heavy lymphocytic infiltrate with large CD30+ cells. The lesion was highly suggestive of cutaneous involvement by malignant lymphoma, but complete regression was observed after cessation of gemcitabine. Although rarely reported, gemcitabine therapy can induce skin lesions. Pathologists should be aware of this possibility in order to avoid a misdiagnosis.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom